Klebsiella Infection Market By Product Type (Diagnostics, Therapeutics, Infection Prevention Technologies); By Application (Hospital-Acquired Infections, Community-Acquired Infections, Surveillance/Outbreak Response); By End User (Hospitals, Laboratories, Clinics, Long-Term Care, Public Health Agencies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Klebsiella Infection Market: Rising Drug Resistance Shifts Hospital Spending Toward Targeted Antibiotics and Rapid Diagnostics

The Global Klebsiella Infection Market is estimated to reach USD 2.88 billion in 2025 and is projected to grow to USD 4.57 billion by 2032, expanding at a CAGR of 6.8% during the forecast period, according to Strategic Market Research.

 

The Klebsiella Infection Market is increasingly shaped by the treatment value of severe and drug-resistant cases rather than overall antibiotic prescription volume. Hospitals are allocating more spending to susceptibility testing, carbapenemase identification, reserve antibiotics, intensive-care support, and infection-control services. Susceptible infections remain a large treatment pool, but most are managed with low-cost generic drugs. Commercial value rises when an isolate produces an extended-spectrum beta-lactamase or carbapenemase, standard empirical therapy fails, and the hospital must use rapid susceptibility testing followed by a restricted or newly approved antibiotic.

 

WHO’s 2025 surveillance findings reinforce this commercial shift by documenting persistently high resistance levels, which are expanding demand for enzyme-specific diagnostics and higher-value hospital therapies. More than 55% of reported Klebsiella pneumoniae bloodstream isolates worldwide were resistant to third-generation cephalosporins. In the African Region, the proportion exceeded 70%. WHO also found that resistance increased in more than 40% of the monitored pathogen–antibiotic combinations between 2018 and 2023, at an average annual rate of 5%–15%. These trends expand demand for carbapenems, protected beta-lactams, rapid antimicrobial susceptibility testing, resistance-gene assays, infectious-disease consultations, and hospital stewardship services. (World Health Organization)

 

The frequently cited 15.1% global carbapenem-resistance figure for K. pneumoniae bloodstream infections should be treated as an earlier GLASS benchmark rather than a current market estimate. More recent surveillance demonstrates wide regional variation and substantially higher resistance in several emerging markets. Commercial models should therefore use country-level susceptibility data rather than applying one global resistance percentage to the entire patient population. (PMC)

 

Severe and Resistant Cases Account for Most Incremental Revenue

Approximately 800,000 deaths were associated with K. pneumoniae infections globally in 2019. Around 642,000 were associated with antimicrobial-resistant infections, while approximately 193,000 were directly attributable to resistance. Lower respiratory tract infections accounted for about 276,000 deaths, bloodstream infections for 265,000, and intra-abdominal infections for 158,000. Together, these syndromes represented almost 90% of Klebsiella-associated mortality. (PMC)

These figures identify the treatment settings in which spending is highest. Bloodstream infections, hospital-acquired pneumonia, neonatal sepsis, complicated intra-abdominal infections, and severe pyelonephritis can require several revenue-generating interventions during one admission:

• Blood cultures and organism identification

• Phenotypic antimicrobial susceptibility testing

• Molecular carbapenemase identification

• Intravenous reserve antibiotics

• Therapeutic-drug and renal-function monitoring

• Intensive-care and ventilation support

• Catheter or device removal

• Abscess drainage and other source-control procedures

Routine susceptible UTIs may generate little pharmaceutical value. The same organism entering the bloodstream can create a prolonged hospital episode involving multiple diagnostic, drug, and service categories. Market forecasts based only on infection incidence will therefore undervalue invasive cases and overvalue uncomplicated infections.

Hypervirulent K. pneumoniae adds another high-acuity segment. Unlike classical hospital-associated strains, hypervirulent lineages can cause liver abscesses, metastatic eye infections, lung abscesses, and central nervous system disease in patients without the traditional risk profile. WHO reported hypervirulent ST23 strains carrying carbapenem-resistance genes across all six WHO regions. The combination of virulence and resistance supports investment in genomic surveillance, virulence-marker assays, vaccines, and antibody-based prevention rather than merely expanding conventional antibiotic volume. (World Health Organization)

 

Drugs Used for Klebsiella Infections: Commercial Value Depends on the Resistance Mechanism

Antibiotic selection must be based on infection site, susceptibility results, local resistance patterns, and the beta-lactamase or carbapenemase produced. A long drug list does not represent interchangeable competition.

Treatment position	Drugs commonly used	Commercial interpretation
Susceptible infections	Ceftriaxone, cefotaxime, cefepime, piperacillin-tazobactam, ciprofloxacin, levofloxacin, gentamicin and amikacin	Mostly mature generic products. Revenue follows admission and testing volume rather than price expansion.
ESBL-producing infections	Ertapenem, meropenem or imipenem-cilastatin	Carbapenems retain a central role, particularly outside uncomplicated urinary infections. Ertapenem can support outpatient parenteral therapy because of its dosing profile.
KPC-producing carbapenem-resistant infections	Meropenem-vaborbactam, ceftazidime-avibactam and imipenem-cilastatin-relebactam; cefiderocol as an alternative	This is an established branded rescue-therapy segment. Formulary access depends on local KPC prevalence and AST availability.
NDM and other metallo-beta-lactamase infections	Ceftazidime-avibactam combined with aztreonam, cefiderocol, or fixed aztreonam-avibactam where approved and indicated	One of the strongest unmet-need segments. NDM prevalence supports demand in South Asia and other high-resistance regions.
OXA-48-like infections	Ceftazidime-avibactam preferred; cefiderocol as an alternative	Particularly relevant in Europe, India, the Middle East, and North Africa. Meropenem-vaborbactam and imipenem-relebactam do not provide equivalent OXA-48 inhibition.
Non-bloodstream and non-urinary resistant infections	Tigecycline or eravacycline in selected cases	Tissue distribution can support use in some intra-abdominal and soft-tissue infections, but low serum and urinary concentrations restrict the addressable market.
Limited-alternative treatment	Colistin or polymyxin-based regimens	Use is increasingly displaced by newer beta-lactams because toxicity and clinical outcomes restrict adoption. Commercial value is concentrated where newer products are unavailable.
Susceptible oral urinary infections	Fluoroquinolones, trimethoprim-sulfamethoxazole, nitrofurantoin in appropriate lower-UTI cases, sulopenem etzadroxil-probenecid and tebipenem pivoxil under their approved populations	Oral products compete through admission avoidance and earlier discharge rather than through activity against every carbapenemase-producing strain.

IDSA places meropenem-vaborbactam, ceftazidime-avibactam, and imipenem-cilastatin-relebactam among the preferred products for KPC-producing infections. The guidance slightly favours meropenem-vaborbactam because of available outcome data and a lower observed risk of emerging resistance than ceftazidime-avibactam. Cefiderocol is positioned as an alternative. (Infectious Diseases Society of America)

For NDM and other metallo-beta-lactamases, IDSA recommends ceftazidime-avibactam with aztreonam or cefiderocol monotherapy. An observational study included in the guidance reported 30-day mortality of 19% with ceftazidime-avibactam plus aztreonam, compared with 44% among patients receiving other regimens that were mainly polymyxin- or tigecycline-based. A later cohort reported mortality of 22% with ceftazidime-avibactam plus aztreonam, 33% with cefiderocol, and 50% with colistin-containing regimens. These non-randomised findings do not establish product superiority, but they explain why hospitals are moving away from older polymyxin-based rescue therapy when newer active beta-lactams are available.

The supplied clinical material reflects some older practice patterns, particularly routine combinations involving colistin, tigecycline, aminoglycosides, and carbapenems. These products remain relevant in access-constrained settings, but they should not be presented as the preferred modern standard when a newer active beta-lactam is available. Current guidance also advises against using tigecycline or eravacycline for bloodstream and urinary infections because their serum and urinary concentrations are inadequate for those indications.

 

Infection Site Creates Separate Product Markets

The same susceptibility result does not create the same drug opportunity across pneumonia, UTI, bacteremia, meningitis, and liver abscess.

Complicated UTI has become the most active regulatory entry point because clinical trials can use microbiological eradication and symptom-resolution endpoints in a defined patient population. This has supported approvals for Exblifep, Zaynich, Utebzi, Vabomere, and several established combinations. The category is commercially attractive because resistant UTIs are common enough to support trials, yet severe enough to justify premium products.

Bloodstream infections carry higher mortality and hospital cost but are more difficult to study through conventional registration trials. New products are therefore often used in bacteremia based on organism susceptibility, guideline recommendations, observational evidence, and indications established in another infection site. Manufacturers that produce credible real-world bloodstream-infection evidence can differentiate their drugs beyond the initial regulatory label.

Pneumonia requires reliable lung exposure. A product with strong in-vitro activity may have limited value if adequate pulmonary concentrations cannot be achieved or if the approved label excludes hospital-acquired pneumonia. European authorisations can sometimes be broader than initial U.S. approvals, creating regional differences in addressable revenue.

Liver abscesses and other deep infections may require drainage. Antibiotic suppliers cannot capture the entire economic value of these cases because treatment revenue is shared with interventional radiology, surgery, imaging, and prolonged follow-up. Hypervirulent liver-abscess cases nevertheless remain strategically important because they can support future vaccine and antibody-development programs.

 

Established Branded Therapies Set a High Barrier for New Entrants

Ceftazidime-avibactam, sold in the United States as Avycaz, has established a strong position against KPC- and OXA-48-like-producing Enterobacterales. Meropenem-vaborbactam, sold as Vabomere, competes particularly in KPC-producing infections. Imipenem-cilastatin-relebactam, sold as Recarbrio, provides another KPC-active option. Cefiderocol, sold as Fetroja, uses a siderophore-mediated uptake mechanism and retains a role against several highly resistant Gram-negative organisms, including selected MBL-producing strains. (Infectious Diseases Society of America)

These products have already secured hospital formulary positions, laboratory breakpoints, clinician familiarity, and procurement relationships. A new entrant cannot compete only by showing laboratory activity against K. pneumoniae. It must offer one or more measurable advantages:

• Coverage of an enzyme not adequately addressed by incumbents

• Lower emergence of resistance

• A broader approved infection label

• Oral administration or shorter infusion requirements

• Better renal or safety management

• Faster and more widely available susceptibility testing

• Evidence of reduced length of stay or lower total treatment cost

 

Exblifep Expands Competition in ESBL-Associated cUTI

The FDA approved Exblifep, combining cefepime and enmetazobactam, in February 2024 for adults with complicated UTIs, including pyelonephritis caused by susceptible organisms such as K. pneumoniae. Enmetazobactam protects cefepime against several serine beta-lactamases, including CTX-M, TEM, and SHV ESBL variants. (FDA Access Data)

Exblifep is commercially positioned closer to the ESBL segment than the entire carbapenem-resistant market. Its value proposition is to preserve a cephalosporin-based option and potentially reduce unnecessary carbapenem exposure. Adoption will depend on whether hospital stewardship teams consider it clinically and economically preferable to generic carbapenems.

Allecra has used licensing partners to extend commercial reach. ADVANZ PHARMA holds rights across several European markets, while Acino obtained rights in Gulf Cooperation Council countries and South Africa. This structure reduces the cost of building independent sales organisations while providing access to hospital procurement networks. It also demonstrates how smaller antibiotic developers can retain product economics without funding a fully integrated global launch.

 

Emblaveo Creates a Fixed Product for MBL-Associated Resistance

The FDA approved Emblaveo, the fixed combination of aztreonam and avibactam, in February 2025 with metronidazole for adults with complicated intra-abdominal infections who have limited or no alternatives. Susceptible K. pneumoniae is included among the designated organisms. The U.S. label notes that the indication is supported by limited clinical safety and efficacy data, which is likely to restrict early use to specialist centres. (FDA Access Data)

Its commercial importance is greater than the initial U.S. label suggests. Aztreonam remains stable against metallo-beta-lactamases such as NDM, while avibactam protects it from accompanying serine beta-lactamases. The fixed product replaces a more operationally complex regimen in which hospitals administer ceftazidime-avibactam and aztreonam separately.

AbbVie holds the U.S. and Canadian commercial position, while Pfizer is responsible for other territories. Europe provides a broader set of authorised infection settings than the first U.S. indication. Consequently, European revenue could be supported by complicated UTIs and hospital-acquired respiratory infections, while U.S. uptake initially remains concentrated in limited-alternative intra-abdominal cases.

 

Zaynich Adds a New Competitor for Difficult Gram-Negative cUTI

The FDA approved Wockhardt’s Zaynich, combining cefepime and zidebactam, in May 2026 for adult complicated UTIs, including pyelonephritis caused by susceptible organisms such as K. pneumoniae. (FDA Access Data)

Zaynich enters a category with several incumbent intravenous combinations. Its commercial positioning therefore depends on activity against difficult resistance mechanisms rather than the total cUTI population. Wockhardt’s ability to secure automated AST support and formulary inclusion will be as important as its approval.

The product also tests whether an Indian-origin antibiotic company can retain more value from a global hospital launch rather than licensing the asset at an early stage. A targeted sales model focused on hospitals with high CRE prevalence could limit launch expenditure. However, low prescription volume, stewardship restrictions, and institutional price negotiations will make rapid revenue expansion difficult.

 

Utebzi Competes Through Oral Administration, Not Maximum Resistance Coverage

The FDA approved GSK’s Utebzi, or tebipenem pivoxil, in June 2026 for complicated UTIs, including pyelonephritis, in adults with limited or no alternative oral treatment options. It is the first oral carbapenem approved in the United States. GSK licensed the product from Spero Therapeutics and expects commercial availability during 2026. (GSK)

The product can alter site-of-care economics by allowing selected patients to avoid intravenous therapy, outpatient infusion, or prolonged hospitalisation. Its commercial comparator is therefore not only another antibiotic. It is the combined cost of an infusion line, nursing time, infusion-centre visits, and additional bed days.

Utebzi does not address every resistant Klebsiella segment. Its label indicates that tebipenem lacks activity against organisms producing KPC, NDM, VIM, and OXA-48 carbapenemases. The product is better positioned in susceptible and selected ESBL-producing infections than in the most difficult carbapenemase-producing cases. This preserves the need for molecular carbapenemase testing before oral step-down treatment is selected.

 

The Reported 65-Asset Pipeline Is Broad but Predominantly Preclinical

A 2024 commercial pipeline snapshot cited in the supplied information tracked 65 Klebsiella-related development assets across 58 companies, universities, and institutes. It classified 37 assets as preclinical, with 53 company-led and 12 academic programs. Intravenous administration was the largest reported route, while small molecules and biologics represented major molecule categories. (Pharmaceutical Technology)

The figure should not be interpreted as 65 realistic future launches. Pipeline databases often include broad Gram-negative antibiotics, discovery-stage targets, university research, dormant projects, platform technologies, and products that have not produced recent public development updates. The large preclinical share indicates conceptual breadth but limited near-term competitive pressure.

The pipeline is strongest in five areas:

1. New beta-lactam and beta-lactamase inhibitor combinations

2. Bacteriophages and phage-derived proteins

3. Vaccines and monoclonal antibodies

4. Peptides, bacteriocins, and precision nucleic-acid therapies

5. Antivirulence, antibiofilm, and host-directed treatments

 

Bacteriophages Are Moving Toward Manufacturing Partnerships

PHAXIAM Therapeutics added K. pneumoniae to its preclinical phage portfolio and entered a strategic collaboration with Technophage in January 2025. The partners targeted a combined collection of 25 GMP phages by the end of 2025 and 35–45 by the end of 2026. The planned portfolio covers at least seven critical pathogens, including K. pneumoniae. (NTB Kommunikasjon)

The collaboration addresses one of the main commercial barriers to phage therapy: a single phage usually covers only a limited group of bacterial strains. A larger GMP library increases the probability of matching a patient isolate and reduces the time needed to prepare an individualised treatment. It also creates recurring revenue prospects through phage screening, susceptibility matching, manufacturing, storage, and hospital delivery.

Locus Biosciences’ LBP-KP01 uses CRISPR-Cas3-enhanced bacteriophages against K. pneumoniae, while GangaGen has developed engineered protein antibiotics known as klebicins. Both programs have appeared in the CARB-X portfolio. Their commercial potential lies in pathogen specificity and reduced disruption of the wider microbiome. Their principal risk is that highly targeted products require rapid confirmation that the patient’s strain is susceptible to the specific phage or protein construct. (Carb-X)

The KLEOPATRA research program received approximately €1.32 million to study phage–antibiotic combinations against K. pneumoniae. Combination development could be more commercially realistic than phage monotherapy because antibiotics provide immediate broad activity while phages target the resistant population. Phage resistance, manufacturing consistency, and strain matching still prevent a conventional large-volume commercial model. (jpiamr.eu)

 

Vaccines Could Create a Preventive Market, but Target-Population Selection Remains Unresolved

CHO Pharma’s CHO-V08 is a bivalent capsular-polysaccharide vaccine targeting hypervirulent K1 and K2 serotypes. The candidate entered Phase I testing in healthy adults, and the company reported in May 2026 that recruitment and dosing had been completed. Immunogenicity and functional-antibody analyses were continuing. (ClinicalTrials.gov)

A successful vaccine would change market economics by preventing infections rather than treating each resistant episode. The commercial challenge is identifying whom to vaccinate. Possible populations include ICU patients, transplant recipients, patients with cancer, residents of long-term-care facilities, people with recurrent UTIs, pregnant women to protect newborns, and populations in regions with a high neonatal-sepsis burden.

A K1/K2 vaccine may address hypervirulent disease but will not necessarily cover the wider serotype distribution of hospital-associated classical K. pneumoniae. Broader O-antigen or multivalent approaches may offer greater population coverage but require more complex manufacturing and clinical validation. A 2025 preclinical MAPS vaccine containing four Klebsiella O-polysaccharides was designed to cover a large proportion of circulating isolates, illustrating the industry’s movement toward wider antigen coverage. No Klebsiella vaccine is currently licensed. (ASM Journals)

Monoclonal antibodies targeting capsular polysaccharides, O-antigens, or biofilm components could be used prophylactically in high-risk hospital populations or as adjunctive treatment. Their price and intravenous administration make broad preventive use unlikely. A more plausible market is a short-duration intervention for narrowly defined patients with a high probability of invasive infection.

 

Precision Antimicrobials Expand the Research Base but Remain Far from Commercial Scale

Pedanius Therapeutics’ PED-018 is a preclinical precision-antimicrobial program directed against a bacterial gene target associated with K. pneumoniae. The company’s platform uses porin translocation to deliver RNA-targeted therapeutics into Gram-negative bacteria. This approach could reduce off-target microbiome damage, but it must overcome bacterial delivery, stability, manufacturing, and strain-coverage challenges. (Synapse)

The broader early-stage pipeline includes synthetic proline-rich antimicrobial peptides, bacteriocins, antisense oligonucleotides, capsule-targeting antibodies, antibiofilm agents, and nanoparticle formulations. These approaches attempt to bypass beta-lactamases, porin loss, efflux pumps, and conventional target-based resistance. The supplied development material identifies examples such as Bac7-derived peptides, PED-018, engineered Klebsiella protein antibiotics, phages, monoclonal antibodies, and nanoparticle-based systems.

Scientific novelty does not guarantee commercial differentiation. Peptides can face rapid degradation and manufacturing costs. Antisense products require efficient bacterial-cell delivery. Nanoparticles need reproducible composition and long-term safety evidence. Antibody products must cover sufficient capsular or O-antigen diversity. These technologies are more likely to create specialist products than high-volume replacements for broad-spectrum antibiotics.

 

Host-Directed Treatment Opens a Separate Sepsis Opportunity

Aurobac Therapeutics licensed a Boehringer Ingelheim compound for development as ATX101. The program targets vascular-integrity loss in septic shock rather than directly killing the infecting bacterium. (Evotec Website (English))

ATX101 should not be counted as a Klebsiella-specific antibiotic. Its relevance lies in a parallel market for host-directed adjuncts. A therapy that reduces vascular leakage, organ dysfunction, or septic-shock progression could be used before the exact pathogen and resistance mechanism are known. This would reduce dependence on the small number of laboratory-confirmed Klebsiella patients required for a pathogen-specific trial.

Host-directed products also avoid direct antibacterial selection pressure. Their commercial challenge is demonstrating a mortality or organ-support benefit on top of antibiotics, fluids, vasopressors, and intensive-care treatment in a clinically heterogeneous sepsis population.

 

Diagnostics Will Capture Revenue from Every New Resistance-Specific Therapy

The growing number of treatment options increases the value of rapid diagnostic information. Hospitals must distinguish KPC, NDM, VIM, IMP, and OXA-48-like enzymes because each mechanism changes the preferred drug.

BioMérieux received FDA clearance in 2024 for its VITEK REVEAL rapid antimicrobial susceptibility system. The platform can produce Gram-negative susceptibility results directly from positive blood cultures in approximately 5.5–6 hours. Faster results increase the probability that a premium targeted antibiotic is started early enough to affect outcomes. They can also shorten unnecessary exposure to broad empirical treatment.

FDA susceptibility criteria now include recently introduced products such as aztreonam-avibactam, cefepime-enmetazobactam, cefepime-zidebactam, cefiderocol, and tebipenem pivoxil. Each approval creates demand for new laboratory panels, disks, software updates, verification work, and staff training. (U.S. Food and Drug Administration)

Diagnostic companies can therefore generate more predictable recurring revenue than some antibiotic developers. Instruments create an installed base, while each blood culture or susceptibility panel generates consumable and service income. Antibiotics remain deliberately restricted through stewardship, whereas diagnostic testing expands whenever a resistant infection is suspected.

 

Commercial Prospects Will Be Strongest in Integrated Treatment Platforms

The Klebsiella Infection Market has a large epidemiological burden but a fragmented revenue base. Generic drugs dominate susceptible infections. Branded antibiotics capture smaller resistant populations. Diagnostics determine which product can be prescribed. Phage and precision therapies require strain matching. Vaccines must define a practical high-risk population.

The most defensible growth opportunities are:

• New antibiotics for NDM-, KPC-, and OXA-48-producing infections

• Oral products that replace prolonged intravenous cUTI treatment

• Rapid phenotypic AST and carbapenemase-gene testing

• Hospital surveillance and genomic outbreak-control platforms

• Phage libraries supported by GMP manufacturing and matching assays

• Multivalent vaccines for neonatal and high-risk hospital populations

• Antibiofilm products for device-associated infections

• Host-directed adjuncts for sepsis and septic shock

The pipeline is broad in research concepts but thin in advanced Klebsiella-specific products. Near-term revenue will continue to come from broad Gram-negative antibiotics whose labels include susceptible K. pneumoniae. Longer-term market expansion depends on linking a targeted product with a diagnostic test, a clearly defined patient population, and a payment model that does not require indiscriminate antibiotic use.

 

Klebsiella Infection Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.88 Billion
Revenue Forecast in 2032	USD 4.57 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Product Type	Diagnostics; Therapeutics; Infection Prevention Technologies
By Application	Hospital-Acquired Infections; Community-Acquired Infections; Surveillance/Outbreak Response
By End User	Hospitals; Laboratories; Clinics; Long-Term Care; Public Health Agencies
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Customization Option	Available upon request